Abstract
This review delves into the dynamic intersection of artificial intelligence (AI) and the pharmaceutical industry, exploring a wide spectrum of clinical and commercial applications, challenges and risks, potential solutions, and future outlooks as these domains converge. With the rapid advancement of AI, this review addresses the profound implications of AI in the life sciences sector, emphasizing its potential to revolutionize drug discovery, clinical trials, personalized medicine, pharmacovigilance, sales, and marketing. While lauding the paradigm-shifting prospects, this paper confronts the ethical, privacy, and bias risks entwined with AI development and deployment. Forward-looking solutions, including fortified data governance frameworks, transparent AI algorithms, and interdisciplinary alliances, stand as bulwarks against these impediments. Furthermore, it considers the possibilities afforded to AI by emergent technologies, such as quantum cloud computing and low-code solutions. In conclusion, this review envisions a future where AI, in collaboration with innovative technologies, reshapes the pharmaceutical landscape. By promoting informed discussions and collaboration, this review seeks to empower the industry to harness the transformative potential of AI in an ethical manner.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
